Overview

A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The study will be a double-blind, randomized, vehicle-controlled study with application of ruxolitinib phosphate cream or vehicle in patients with stable plaque psoriasis. Application will be QD for 12 weeks without occlusive dressings. There will be 4 treatments of 50 subjects each.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation